EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$9.10 USD
+0.22 (2.48%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $9.09 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for EYEPOINT PHARMACEUTICALS, INC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 331 | 145 | 212 | 45 | 22 |
Receivables | 1 | 16 | 18 | 9 | 11 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 3 | 4 | 5 | 2 |
Other Current Assets | 9 | 10 | 4 | 3 | 6 |
Total Current Assets | 345 | 173 | 238 | 63 | 42 |
Net Property & Equipment | 5 | 1 | 0 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 23 | 25 | 28 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 355 | 180 | 263 | 92 | 73 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 6 | 7 | 5 | 4 |
Current Portion Long-Term Debt | 0 | 10 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 18 | 16 | 14 | 8 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 39 | 1 | 1 | 1 | 0 |
Total Current Liabilities | 63 | 35 | 24 | 15 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 21 | 14 | 15 | 16 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 29 | 37 | 38 | 47 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 2 | 2 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 89 | 84 | 79 | 73 | 65 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,008 | 767 | 753 | 528 | 473 |
Retained Earnings | -742 | -671 | -569 | -511 | -465 |
Other Equity | 1 | 1 | 1 | 1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 266 | 96 | 184 | 19 | 8 |
Total Liabilities & Shareholder's Equity | 355 | 180 | 263 | 92 | 73 |
Total Common Equity | 266 | 96 | 184 | 19 | 8 |
Shares Outstanding | 47.00 | 34.00 | 33.80 | 18.10 | 10.80 |
Book Value Per Share | 5.67 | 2.83 | 5.46 | 1.02 | 0.77 |
Fiscal Year End for EYEPOINT PHARMACEUTICALS, INC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 280 | 299 | 331 | 136 | 143 |
Receivables | 1 | 3 | 1 | 0 | 11 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 4 | 4 | 5 | 4 |
Other Current Assets | 10 | 11 | 9 | 9 | 9 |
Total Current Assets | 295 | 318 | 345 | 150 | 167 |
Net Property & Equipment | 7 | 7 | 5 | 4 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 324 | 329 | 355 | 160 | 176 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 7 | 7 | 10 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 16 | 18 | 13 | 15 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 33 | 38 | 39 | 40 | 42 |
Total Current Liabilities | 62 | 63 | 63 | 64 | 69 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 12 | 12 | 21 | 32 | 44 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 96 | 79 | 89 | 101 | 118 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,030 | 1,020 | 1,008 | 786 | 772 |
Retained Earnings | -802 | -771 | -742 | -728 | -715 |
Other Equity | 1 | 1 | 1 | 1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 228 | 250 | 266 | 59 | 57 |
Total Liabilities & Shareholder's Equity | 324 | 329 | 355 | 160 | 176 |
Total Common Equity | 228 | 250 | 266 | 59 | 57 |
Shares Outstanding | 52.10 | 52.00 | 47.00 | 35.30 | 34.90 |
Book Value Per Share | 4.38 | 4.81 | 5.67 | 1.66 | 1.64 |